Table of Contents
Executive Summary — 7
SWOT
Analysis — 9
Serbia Pharmaceuticals And Healthcare
Industry SWOT — 9
Serbia Political
SWOT — 10
Serbia Economic SWOT — 10
Serbia Business Environment SWOT — 11
Pharmaceutical
Business Environment Ratings — 12
Table: Emerging Europe -
Regional Pharmaceutical Business Environment Ratings for
Q409 — 12
Limits Of Potential
Returns — 13
Risks To Realisation Of
Returns — 13
Serbia – Market
Summary — 15
Regulatory Regime — 16
Intellectual Property Environment — 17
IP
Disputes — 18
Pricing Regime — 18
Reimbursement Regime — 19
Table Serbia - Examples of
Reimbursed Medicines by Category — 20
Price
Cuts — 21
Price Rises — 21
Industry
Trends and Developments — 23
Epidemiology — 23
Table: Disease Burden In
CEE — 25
Healthcare Sector — 25
Table
Serbia – Major General And Specialised
Hospitals — 26
Recent Healthcare Sector
Developments — 27
Healthcare
Insurance — 28
Healthcare Reform — 29
Medical Tourism — 29
Table: Cosmetic Surgery
Costs — 29
Clinical Trials — 30
Table:
Number Of Ongoing Clinical Trials In Serbia — 31
Medical
Devices — 31
Medical Device Classification In
Serbia — 32
Industry Forecast
Scenario — 33
Overall Market
Forecast — 33
Table: Serbia – Drug Expenditure
Indicators, Historical Data and Forecasts — 34
Key Growth
Factors – Industry — 35
Table: Serbia – Health
Expenditure Indicators, Historical Data And Forecasts — 36
Key Growth Factors – Macroeconomic — 36
Table:
Serbia – Economic Activity, 2006-2013 — 38
Prescription Market Forecast — 39
Table: Serbia –
Prescription Market Indicators, Historical Data And Forecasts (RSDmn unless
otherwise stated) — 40
Table Serbia – Defined Daily
Dose (DDD) Per 1,000 Inhabitants — 41
Patented Market
Forecast — 42
Table: Serbia – Patented Market
Indicators, Historical Data And Forecasts — 43
Generics
Market Forecast — 44
Table: Serbia – Generics Market
Indicators, Historical Data And Forecasts — 45
OTC Market
Forecast — 46
Table: Serbia – OTC Market Indicators,
Historical Data And Forecasts (RSDmn unless otherwise
stated) — 47
Table Serbia – Sales Of Herbal Remedies
2007 — 47
Medical Device Market
Forecasts — 48
Table: Serbia - Medical Device Market,
Historical Data and Forecasts (US$mn unless otherwise
stated) — 48
Pharmaceutical Trade
Forecasts — 49
Table: Serbia – Pharmaceutical Trade
Indicators, Historical Data And Forecasts (US$mn unless otherwise
stated) — 50
Other Healthcare Data
Forecasts — 51
Table: Serbia – Other Healthcare
Indicators, Historical Data And Forecasts — 51
Key Risks
to BMI’s Forecast Scenario — 52
Competitive
Landscape — 53
Pharmaceutical
Sector — 53
Table: Companies Involved In The Serbian
Pharmaceutical Industry — 54
Domestic Pharmaceutical
Industry — 54
Domestic Company
Activity — 55
Foreign Pharmaceutical
Industry — 57
Foreign Company
Activity — 58
Table: Proposed Members Of Serbia’s
Pharmaceutical Industry Association — 59
Pharmaceutical
Wholesale And Retail — 59
Company
Monitor — 61
Multinational Company
Profiles — 61
Pfizer — 61
GlaxoSmithKline — 62
Novartis — 63
Sanofi-Aventis — 64
Merck & Co — 65
Indigenous Company Profiles — 66
Hemofarm
(Stada) — 66
Galenika — 70
Zdravlje
Actavis — 72
Jugoremedija — 75
Country
Snapshot: Serbia Demographic Data — 77
Section 1:
Population — 77
Table: Demographic Indicators,
2005-2030 — 77
Table: Rural/Urban Breakdown,
2005-2030 — 78
Section 2: Education And
Healthcare — 78
Table: Education,
2000/01 — 78
Table: Vital Statistics,
2005-2030 — 78
Section 3: Labour Market And Spending
Power — 79
Table: Employment Indicators,
2001-2006 — 79
Table: Average Annual Manufacturing Wages,
2000-2012 — 79
BMI Methodology — 80
How We Generate Our Pharmaceutical Industry Forecasts — 80
Pharmaceutical Business Environment Ratings
Methodology — 81
Ratings Overview — 81
Table: Pharmaceutical Business Environment Indicators — 82
Weighting — 83
Table: Weighting Of
Components — 83
Sources — 83
| 
View Cart
